Xenetic Biosciences, Inc. (NASDAQ:XBIO) Files An 8-K Entry into a Material Definitive Agreement

ME Staff 8-k
-
0

Xenetic Biosciences, Inc. (NASDAQ:XBIO) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.

On July 16, 2019, Xenetic Biosciences, Inc. (the “Company”), in connection with a potential financing transaction, entered into a consent agreement (the “Consent Agreement”) with certain holders (the “Holders”) of warrants to purchase shares of the Company’s common stock whose consent was sought in connection with a potential financing transaction. In consideration of the Holders’ consent, the Company agreed to (i) issue the Holders an aggregate of 16,666 shares of the Company’s common stock and (ii) adjust the exercise price of those certain warrants (each a "Warrant") issued to each Holder in connection with the Company\’s reverse stock split on June 25, 2019, as described in the Consent Agreement.

A copy of the Consent Agreement is filed as Exhibit 10.1 to this report and is incorporated herein by reference.

The issuance of the shares was not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were issued in reliance on the exemption from registration afforded by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering.

  

The information required by this Item 3.02 is incorporated by reference to Item 1.01 set forth above.

(d) Exhibits


Xenetic Biosciences, Inc. Exhibit
EX-10.1 2 xenetic_ex1001.htm CONSENT AGREEMENT Exhibit 10.1   CONSENT AGREEMENT   This Consent Agreement (this "Consent Agreement"),…
To view the full exhibit click here

About Xenetic Biosciences, Inc. (NASDAQ:XBIO)

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.